Last reviewed · How we verify
HLD-0915
At a glance
| Generic name | HLD-0915 |
|---|---|
| Sponsor | Halda Therapeutics OpCo, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLD-0915 CI brief — competitive landscape report
- HLD-0915 updates RSS · CI watch RSS
- Halda Therapeutics OpCo, Inc. portfolio CI